IntelliPharmaCeutics International (TSXV:IPCI) EBIT per Share : C$-0.11 (TTM As of Aug. 2023)

View and export this data going back to 1999. Start your Free Trial

What is IntelliPharmaCeutics International EBIT per Share?

IntelliPharmaCeutics International's EBIT per Share for the three months ended in Aug. 2023 was C$-0.07. Its EBIT per Share for the trailing twelve months (TTM) ended in Aug. 2023 was C$-0.11.

During the past 3 years, the average EBIT per Share Growth Rate was 37.80% per year. During the past 5 years, the average EBIT per Share Growth Rate was 53.30% per year. During the past 10 years, the average EBIT per Share Growth Rate was 31.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for IntelliPharmaCeutics International's EBIT per Share or its related term are showing as below:

TSXV:IPCI' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -44.3 Med: 10.8 Max: 63.6
Current: 37.8

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of IntelliPharmaCeutics International was 63.60% per year. The lowest was -44.30% per year. And the median was 10.80% per year.

TSXV:IPCI's 3-Year EBIT Growth Rate is ranked better than
86.96% of 1311 companies
in the Biotechnology industry
Industry Median: 3.7 vs TSXV:IPCI: 37.80

IntelliPharmaCeutics International's EBIT for the three months ended in Aug. 2023 was C$-2.39 Mil.

IntelliPharmaCeutics International EBIT per Share Historical Data

The historical data trend for IntelliPharmaCeutics International's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IntelliPharmaCeutics International EBIT per Share Chart

IntelliPharmaCeutics International Annual Data

Trend

Nov13

Nov14

Nov15

Nov16

Nov17

Nov18

Nov19

Nov20

Nov21

Nov22

EBIT per Share

Get a 7-Day Free Trial

-3.74

-0.48

-0.13

-0.20

-0.11

IntelliPharmaCeutics International Quarterly Data
	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23
EBIT per Share	Get a 7-Day Free Trial															-0.01	-0.02	-0.01	-	-0.07

IntelliPharmaCeutics International EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

IntelliPharmaCeutics International's EBIT per Share for the fiscal year that ended in Nov. 2022 is calculated as

	EBIT per Share		(A: Nov. 2022 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-3.492	/	33.093
=	-0.11

IntelliPharmaCeutics International's EBIT per Share for the quarter that ended in Aug. 2023 is calculated as

	EBIT per Share		(Q: Aug. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-2.39	/	33.093
=	-0.07

EBIT per Share for the trailing twelve months (TTM) ended in Aug. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.11

IntelliPharmaCeutics International (TSXV:IPCI) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

IntelliPharmaCeutics International EBIT per Share Related Terms

Thank you for viewing the detailed overview of IntelliPharmaCeutics International's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

IntelliPharmaCeutics International (TSXV:IPCI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IntelliPharmaCeutics International Inc (TSXV:IPCI) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

IPCIF:USA I4AA:Germany

Address

30 Worcester Road, Toronto, ON, CAN, M9W 5X2

Website

https://www.intellipharmaceutics.com

IntelliPharmaCeutics International Inc is a pharmaceutical company. The company is engaged in the research, development, and manufacturing of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of a range of existing and new pharmaceuticals. Its ongoing drug development programs are at various stages of development in therapeutic areas that include neurology, cardiovascular, GIT, and pain. The company's product, a generic of Focalin XR, is partnered with Par Pharmaceutical, Inc. and received FDA approval. It derives revenue from the United States.

IntelliPharmaCeutics International (TSXV:IPCI) Headlines

No Headlines